Phase I Clinical Study of YL-15293 in Patients With Advanced Solid Tumor With KRAS Mutation

NCT05173805 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

150

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumor

Interventions

DRUG: YL-15293

Sponsor

Shanghai YingLi Pharmaceutical Co. Ltd.